SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001571049-16-019239
Filing Date
2016-10-31
Accepted
2016-10-31 16:56:57
Documents
3
Group Members
CELGENE ALPINE INVESTMENT CO. III, LLC

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D t1602584_sc13d.htm SC 13D 78516
2 EXHIBIT 1 t1602584_ex-1.htm EX-1 4894
3 EXHIBIT 2 t1602584_ex-2.htm EX-2 20466
  Complete submission text file 0001571049-16-019239.txt   105367
Mailing Address 86 MORRIS AVENUE SUMMIT NJ 07901
Business Address 86 MORRIS AVENUE SUMMIT NJ 07901 (908)673-9000
CELGENE CORP /DE/ (Filed by) CIK: 0000816284 (see all company filings)

IRS No.: 222711928 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D
SIC: 2834 Pharmaceutical Preparations

Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 6173154600
CRISPR Therapeutics AG (Subject) CIK: 0001674416 (see all company filings)

IRS No.: 473173478
Type: SC 13D | Act: 34 | File No.: 005-89674 | Film No.: 161962285
SIC: 2836 Biological Products, (No Diagnostic Substances)